Xickle® RBC-Plus™ is available now. WHY WAIT. Live a Healthier Life!
Connect With Us

Big News: Clinical Trials Starting Soon!

January 12, 2015 by Andrea

clinical trial post pic

We've got some really big news coming over the next several weeks and months -- Xickle will be making major moves in 2015! Here's a sneak peek of what's coming: 

For the past couple of years, we've been working toward not only raising awareness for sickle cell, but also developing Xickle RBC-Plus as an FDA-approved product and getting it ready for clinical trials. Currently, Xickle RBC-Plus is only sold as an all-natural supplement, but over the course of the next few months, we'll begin posting updates about the start of our clinical trial, as well as its progress. 

During the trials, participants will be given specified doses of  the "drug equivalent"  of Xickle RBC-Plus. After a determined amount of time taking the drug -- and at certain intervals throughout the process -- blood will be drawn from each participant. Once drawn, that blood will then be purposefully placed under hypoxic (low oxygen) conditions to see how the red blood cells react. If the cells do not sickle, that will show that, indeed, the drug is working and the effects can now be precisely measured. 

The FDA drug approval process will take 4-6 years. However, the FDA still allows us to sell Xickle RBC-Plus as a supplement with structure functions claims, but without medical claims. And we can do a lot of good during those 4-6 years. We already have many customers across the world using Xickle RBC-Plus in its supplement form and they are having positive results -- check out a few of their testimonials

Thank you all for your continued support! And remember, follow us on Twitter and Facebook for the latest updates! Happy New Year! 



Sign Up For Xickle's Newsletter!

Get the latest news, health tips and special offers!








Click to access the login or register cheese
Subscribe To Our Newsletter

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!